Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Department of Physiology, Anatomy & Genetics (DPAG) scientists develop single-cell oxygen saturation imaging to study oxygen handling by red blood cells. New physiological techniques that measure the blood's oxygen saturation are particularly important in light of the current pandemic, as COVID-19 patients present an abnormally low concentration of oxygen in the blood.

Oxygen saturation of blood is a fundamental clinical parameter that assesses how much oxygen is being carried by red blood cells (RBCs). The importance of these so-called oximetery measurements is highlighted by the current COVID-19 crisis because patients present a profound drop in blood oxygen, known as hypoxaemia. However, another aspect of oxygen handling by blood that is not currently measured is the speed with which RBCs exchange gases. Indeed, routinely performed tests for gas-carrying capacity (for example, total hemoglobin) cannot determine how fast RBCs take-up and release oxygen. Such information is critical for evaluating the physiological fitness of RBCs, which have less than one second to exchange large volumes of oxygen in the lungs and tissues.

To address this problem, a team led by Associate Professor Pawel Swietach has designed a method to quantify gas exchange in individual RBCs. Applying this method to various blood disorders has highlighted the barriers to efficient gas exchange. The results identify the adaptations that allow healthy RBCs to exchange gases quickly, and explain how disease-related changes may impair oxygen transport.

Read the full story on the Department of Physiology, Anatomy & Genetics (DPAG) website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.